| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.41 | 60.2% | 70.5% |
| Total Income | 0.41 | 60.2% | 70.5% |
| Expenditure | 9.47 | 16.2% | 223.2% |
| PBT | — | ||
| Net Profit | -9.01 | 29.6% | 274.9% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.31 | 24.8% | 6650.0% |
Cerenome Reports Q2 2026 Financial Results and Business Update
15 Aug 2026 · 15 Aug, 2:06 am
Summary
Cerenome, Inc. announced its financial results for the second quarter ended June 30, 2026, and provided business updates, including a rebranding from Plus Therapeutics, Inc. The company reported a net loss of $9.0 million for the quarter, a change from the net income reported in the prior year, primarily due to increased operating expenses related to commercial operations and clinical trial funding. Significant business progress was noted, including continued enrollment in key clinical trials for REYOBIQ™ and advancements in the CNSide® CSF Assay Platform, such as achieving payer coverage objectives and obtaining Medicare billing identifiers. Management expressed optimism for accelerating progress across all verticals in the remainder of the year.
Key Highlights
- 1
Cerenome, Inc. reported financial results for the second quarter ended June 30, 2026, alongside recent corporate updates.
- 2
The company rebranded from Plus Therapeutics, Inc. to Cerenome, Inc. effective August 3, 2026.
- 3
Enrollment continued in the ReSPECT-LM clinical trial, with approximately one-third of patients enrolled as of June 30, 2026, and no dose-limiting toxicities observed.
- 4
The CNSide® CSF Assay Platform performed 232 tests in the first half of 2026 and achieved its corporate objective for contracted commercial payer coverage of 150 million covered lives by mid-year.
- 5
Cerenome received Medicare Provider Transaction Access Number and a dedicated American Medical Association billing identifier for CNSide.
- 6
The company reported a net loss of $9.0 million, or $1.31 per basic share, for the second quarter of 2026, compared to a net income of $5.2 million, or $0.62 per basic share, for the second quarter of 2025.
- 7
Cash, cash equivalents, and investments were $8.6 million as of June 30, 2026.
Management Comments
Marc H. Hedrick
M.D., M.B.A.
Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company. For the remainder of the year, I expect the progress to accelerate across all verticals, highlighted by our buildout of the diagnostic commercial organization.
Informational and educational content only. Not investment advice.